 This study found that taking aspirin regularly can reduce the risk of developing hepatocellular cosonoma, HCC, by up to 30 percent. The reduction was more pronounced in Asian populations, where it was estimated to be 19 percent. In addition, the study also found that aspirin could reduce the risk of HCC in patients with chronic liver diseases such as hepatitis B virus, HBV, and hepatitis C virus, HCV, infections by 19 percent and 24 percent, respectively. However, the study also noted that aspirin administration may increase the risk of gastrointestinal bleeding in these patients. This article was offered by Shui Wang, the duans were Zhao Jinlin, and others.